Integral Health Asset Management LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 150,000 shares of the biopharmaceutical company's stock, valued at approximately $4,515,000. Integral Health Asset Management LLC owned approximately 0.10% of TG Therapeutics as of its most recent filing with the SEC.
Several other institutional investors have also recently made changes to their positions in TGTX. Arizona State Retirement System increased its position in TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after buying an additional 364 shares in the last quarter. Blue Trust Inc. increased its position in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares in the last quarter. Summit Investment Advisors Inc. increased its position in TG Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 463 shares in the last quarter. Brookstone Capital Management increased its position in TG Therapeutics by 3.7% during the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock valued at $527,000 after buying an additional 624 shares in the last quarter. Finally, Daymark Wealth Partners LLC increased its position in TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after buying an additional 689 shares in the last quarter. Institutional investors own 58.58% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on TGTX shares. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $40.80.
Read Our Latest Report on TGTX
TG Therapeutics Stock Up 0.1%
Shares of TG Therapeutics stock traded up $0.03 on Wednesday, reaching $33.40. The company's stock had a trading volume of 1,767,443 shares, compared to its average volume of 3,012,877. The company has a market capitalization of $5.30 billion, a price-to-earnings ratio of -333.97 and a beta of 2.21. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm's fifty day simple moving average is $38.76 and its two-hundred day simple moving average is $33.78.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business's quarterly revenue was up 90.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.07) earnings per share. Equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.
TG Therapeutics Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Further Reading
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
